# EDIT — slm-full-cpu

## Metadata

ticker: EDIT
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 8d5ea64d49456b5719af6f206e5869311c6400f5dc68630c57f6a64c62d06931
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 704, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 160.163, "latency_s_total": 160.163, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 594, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 146.209, "latency_s_total": 146.209, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 119, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 41.627, "latency_s_total": 41.627, "parse_failure": 0, "prompt_tokens": 652, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 169, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 54.964, "latency_s_total": 54.964, "parse_failure": 0, "prompt_tokens": 646, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 171, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 68.115, "latency_s_total": 68.115, "parse_failure": 0, "prompt_tokens": 666, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 186, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 77.39, "latency_s_total": 77.39, "parse_failure": 0, "prompt_tokens": 784, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 963, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 144.176, "latency_s_total": 144.176, "parse_failure": 0, "prompt_tokens": 1668, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.735,
  "currency": "USD",
  "market_cap": 420041376.0,
  "forward_pe": -3.631511,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to fund ongoing operations, research, and development. If capital cannot be raised when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research programs or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Funding Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with Bristol Myers Squibb Company (BMS) and retained portions of contingent upfront payments under a license agreement with Vertex Pharmaceuticals.
*   **Future Financing:** Until substantial product revenues are generated, the company expects to finance cash needs through public or private equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. Raising additional capital may cause dilution to stockholders or require relinquishing rights to technologies.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It is expected to be many years, if ever, before a product candidate is ready for commercialization.
*   **Primary Candidate:** A significant portion of expenses and efforts is devoted to the preclinical and clinical development of EDIT-401.
*   **Profitability Uncertainty:** The company does not expect to achieve profitability in the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Commercialization Challenges:** If product candidates receive marketing approval, the company will incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution, unless these responsibilities fall to a collaborator.

**Risk Factors**
*   **Regulatory and Development Risks:** Identifying product candidates and conducting clinical trials is time-consuming, expensive, and uncertain. The company may never generate the necessary data to obtain marketing approval. Expenses could increase beyond expectations if regulatory authorities (such as the FDA or EMA) require additional studies.
*   **Economic and Political Risks:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Intellectual Property and Collaboration Risks:** Costs related to patent applications, maintaining intellectual property rights, and defending claims are significant. The success of the business also depends on collaborations, such as the one with BMS, and the ability to establish additional favorable partnerships.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

**Financial Position and Capital Needs**
*   **Significant Losses and Deficit:** The company has incurred significant operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion.
*   **Uncertain Path to Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Need for Additional Funding:** Substantial additional funding is required to support ongoing activities, including preclinical studies and clinical trials for EDIT-401 and other product candidates. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research and development programs or commercialization efforts.
*   **Limited Committed Funds:** As of December 31, 2025, existing cash and cash equivalents are expected to fund operations only into the third quarter of 2027. The only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with Bristol Myers Squibb Company (BMS) and retained portions of payments under a license agreement with Vertex Pharmaceuticals.
*   **Dilution and Restrictions:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Operational and Development Risks**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It may take many years, if ever, before a product candidate is ready for commercialization.
*   **Expenses and Costs:** Expenses are expected to increase substantially due to continued research and development, clinical trials, intellectual property maintenance, and potential commercialization infrastructure. Costs may also exceed expectations if regulatory authorities require additional studies.
*   **Commercialization Challenges:** Even if products receive marketing approval, the company may not generate significant revenues. Commercialization requires establishing sales, marketing, and distribution infrastructure, which involves significant expense and uncertainty.

**External and Economic Factors**
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Regulatory Risks:** The costs, timing, and outcomes of regulatory reviews are uncertain factors that impact capital requirements and commercial viability.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.735 with a market capitalization of approximately $420 million. The company reported revenue of $47 million but continues to operate at a significant loss, resulting in a negative net income of $73.9 million and a profit margin of -157.32%. Consequently, the forward P/E ratio is negative, reflecting the absence of profitability. As a pre-profit biotechnology firm, EDIT remains heavily reliant on external capital to fund its operations and development pipelines.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to face significant financial headwinds, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%, underscoring the company's reliance on external capital to sustain operations. The stock is currently trading near its 52-week low of $1.66 at $2.735, reflecting investor caution amid ongoing profitability challenges and the inherent risks associated with early-stage biotechnology development. While recent SEC filings highlight standard risk disclosures regarding forward-looking statements and potential capital needs, no major clinical or commercial breakthroughs have been reported to shift the current sentiment. Investors should remain vigilant regarding the company's cash burn rate and the timeline for achieving sustainable revenue growth amidst a competitive gene-editing landscape.

### SEC Filing Highlights
Editas Medicine reported a net loss of $160.1 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical stage with no products yet commercialized. The company’s existing cash and cash equivalents are projected to fund operations and capital expenditures through the third quarter of 2027, after which it will require substantial additional financing. Primary external funding sources are limited to contingent payments from collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals, highlighting the company's reliance on future equity or debt offerings. With its most advanced candidate, EDIT-401, still in preclinical testing, management does not expect to achieve profitability in the foreseeable future. Consequently, the company faces significant risks related to its ability to raise capital on attractive terms and sustain ongoing research and development efforts.

### Risk Factors

*   **Substantial Financial Losses and Capital Constraints:** The company has incurred significant operating losses and an accumulated deficit of $1.6 billion, with existing cash reserves expected to fund operations only through Q3 2027, necessitating additional funding that may result in dilution or restrictive covenants.
*   **Early-Stage Development and Uncertain Commercialization:** Most product candidates remain in preclinical stages, meaning there is no guarantee of regulatory approval or successful commercialization, and the company may never achieve sustainable profitability.
*   **Dependence on External Collaborations and Macroeconomic Volatility:** Future liquidity relies heavily on contingent payments from partners like Bristol Myers Squibb and Vertex, while unfavorable economic or political conditions could disrupt supply chains, weaken demand, or hinder access to capital markets.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a preclinical-stage gene-editing company with a $420 million market capitalization, currently navigating a challenging financial landscape marked by a $1.6 billion accumulated deficit and reliance on external capital to fund its pipeline. The stock is notable for its proximity to 52-week lows and the imminent need for substantial additional financing beyond the third quarter of 2027, as it lacks commercialized products or near-term profitability. The single most important near-term variable shaping the investment outcome is the company’s ability to secure favorable financing terms or generate contingent payments from key partners like Bristol Myers Squibb and Vertex Pharmaceuticals to extend its cash runway.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, characterized by high execution risk and significant capital requirements in the absence of commercial revenue. Key variables to monitor include the progress of the EDIT-401 candidate in preclinical testing, the realization of contingent payments from strategic collaborations, and the company's success in accessing capital markets before its cash reserves are depleted in the third quarter of 2027. The investment thesis would strengthen if the company demonstrates clear pathways to regulatory approval or secures non-dilutive funding that extends its operational runway; conversely, the view would weaken if financing efforts result in severe dilution, if clinical timelines slip, or if macroeconomic conditions restrict access to necessary liquidity.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "a $420 million market capitalization"
LABEL: SUPPORTED
REASON: The raw source data lists `market_cap: 420041376.0`, which rounds to approximately $420 million, and the pre-written Financial Health section states "market capitalization of approximately $420 million."

---

CLAIM: "a $1.6 billion accumulated deficit"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the accumulated deficit stood at $1.6 billion," and the SEC Filing Highlights pre-written section confirms this figure.

---

CLAIM: "proximity to 52-week lows"
LABEL: SUPPORTED
REASON: The current price is $2.735, the 52-week low is $1.66, and the 52-week high is $4.537; the current price is ($2.735 − $1.66) / ($4.537 − $1.66) = $1.075 / $2.877 ≈ 37.4% of the way up from the low, placing it in the lower portion of the range, which arithmetically supports "proximity to 52-week lows."

---

CLAIM: "imminent need for substantial additional financing beyond the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027," confirming the Q3 2027 cash runway limit and the need for financing beyond that point.

---

CLAIM: "lacks commercialized products"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "the company's most advanced research programs are currently in the preclinical testing stages" and "before a product candidate is ready for commercialization," and the SEC Filing Highlights pre-written section states "no products yet commercialized."

---

CLAIM: "near-term profitability" (lacks near-term profitability)
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "The company does not expect to achieve profitability in the foreseeable future," directly supporting the claim that near-term profitability is absent.

---

CLAIM: "contingent payments from key partners like Bristol Myers Squibb and Vertex Pharmaceuticals"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and the pre-written SEC Filing Highlights section explicitly name Bristol Myers Squibb and Vertex Pharmaceuticals as the sources of contingent payments under collaboration/license agreements.

---

**OUTLOOK**

---

CLAIM: "progress of the EDIT-401 candidate in preclinical testing"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "A significant portion of expenses and efforts is devoted to the preclinical and clinical development of EDIT-401," and the pre-written SEC Filing Highlights section confirms "EDIT-401, still in preclinical testing."

---

CLAIM: "cash reserves are depleted in the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state existing cash is expected to fund operations "into the third quarter of 2027," directly supporting this claim.

---

CLAIM: "realization of contingent payments from strategic collaborations"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly identify contingent payments from BMS and Vertex Pharmaceuticals as the only significant committed potential external funding sources, supporting this as a key variable.

---

CLAIM: "if financing efforts result in severe dilution"
LABEL: SUPPORTED
REASON: The RAG Risk Factors explicitly state "Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders," directly grounding this forward-looking risk scenario.

---

CLAIM: "if macroeconomic conditions restrict access to necessary liquidity"
LABEL: SUPPORTED
REASON: The RAG Risk Factors explicitly state "Unfavorable national or global economic conditions… could adversely affect the business by… making it difficult to raise capital on acceptable terms," directly grounding this risk scenario.

---

**SUMMARY NOTE:** No quantitative figures (e.g., specific price targets, specific ratio values, specific percentage thresholds, or specific dollar amounts beyond those already audited above) appear in the Outlook section beyond those already evaluated. All audited claims are SUPPORTED. No claims were found to be UNSUPPORTED or INFERENCE.
